CLAREMONT-BASED healthcare company Resonance Health Ltd this week announced a deeply discounted $3.06 million entitlements offer at two cents per share to fund further development of FibroScreen, a non-invasive liver fibrosis test using magnetic resonance imaging.
27/06/2006 - 22:00
Resonance offer
27/06/2006 - 22:00
